drugset / Trial / NCT06151236
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Timeline
- Start
- 2024-03-11
- Primary completion
- 2026-12
- Completion
- 2034-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | — |